Nuveen’s Fennec Pharmaceuticals FENC Stock Holding History

Nuveen’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$375K	Buy	60,948 +34,942	+134%	+$270K	﹤0.01%	2943
2025 Q4	$200K	Hold	26,006	–	–	﹤0.01%	3141
2025 Q3	$243K	Hold	26,006	–	–	﹤0.01%	3106
2025 Q2	$216K	Hold	26,006	–	–	﹤0.01%	3141
2025 Q1	$158K	Hold	26,006	–	–	﹤0.01%	3160
2024 Q4	$164K	Hold	26,006	–	–	﹤0.01%	3233
2024 Q3	$130K	Hold	26,006	–	–	﹤0.01%	3286
2024 Q2	$159K	Hold	26,006	–	–	﹤0.01%	3258
2024 Q1	$289K	Buy	26,006 +1,545	+6%	+$15.5K	﹤0.01%	3109
2023 Q4	$274K	Hold	24,461	–	–	﹤0.01%	3162
2023 Q3	$248K	Hold	24,461	–	–	﹤0.01%	2999
2023 Q2	$304K	Buy	+24,461	New	+$203K	﹤0.01%	3015
2021 Q2	–	Sell	-101,369	Closed	-$630K	–	3426
2021 Q1	$630K	Sell	101,369 -4,680	-4%	-$35.2K	﹤0.01%	3042
2020 Q4	$790K	Buy	106,049 +2,439	+2%	+$18.6K	﹤0.01%	2890
2020 Q3	$628K	Buy	103,610 +27,800	+37%	+$196K	﹤0.01%	2869
2020 Q2	$633K	Buy	+75,810	New	+$564K	﹤0.01%	2811

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Nuveen's FENC Position: Q1 2026 in Review

Nuveen increased its Fennec Pharmaceuticals (FENC) stake by 134% in Q1 2026, buying an estimated $270K and bringing the position to 60,948 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #2943.

Nuveen first reported a position in FENC in Q2 2020 and has held it in 16 quarters since. The position peaked at $790K in Q4 2020. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

Nuveen held 60,948 shares of Fennec Pharmaceuticals worth $375K as of Q1 2026.
Nuveen bought 34,942 Fennec Pharmaceuticals shares in Q1 2026, an estimated $270K.
Fennec Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2943 holding.
Nuveen first reported a position in Fennec Pharmaceuticals in Q2 2020 and has held it in 16 quarters since.
Nuveen's Fennec Pharmaceuticals position peaked at $790K in Q4 2020.
90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.